Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Neuropeptide FF receptors have opposing modulatory effects on nociception.

Lameh J, Bertozzi F, Kelly N, Jacobi PM, Nguyen D, Bajpai A, Gaubert G, Olsson R, Gardell LR.

J Pharmacol Exp Ther. 2010 Jul;334(1):244-54. doi: 10.1124/jpet.109.164384. Epub 2010 Mar 30.

2.

Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.

Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, Fejzic A, Thygesen MB, Tabatabaei A, Bradley SR, Gardell LR, Piu F, Olsson R.

J Med Chem. 2009 Nov 26;52(22):7186-91. doi: 10.1021/jm901149c.

PMID:
19856921
3.

Discovery of selective nonpeptidergic neuropeptide FF2 receptor agonists.

Gaubert G, Bertozzi F, Kelly NM, Pawlas J, Scully AL, Nash NR, Gardell LR, Lameh J, Olsson R.

J Med Chem. 2009 Nov 12;52(21):6511-4. doi: 10.1021/jm9011998.

PMID:
19803524
4.

Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.

Pettersson H, Bülow A, Ek F, Jensen J, Ottesen LK, Fejzic A, Ma JN, Del Tredici AL, Currier EA, Gardell LR, Tabatabaei A, Craig D, McFarland K, Ott TR, Piu F, Burstein ES, Olsson R.

J Med Chem. 2009 Apr 9;52(7):1975-82. doi: 10.1021/jm801534c.

PMID:
19338356
5.

Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.

Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW.

J Neurosci. 2008 Nov 5;28(45):11593-602. doi: 10.1523/JNEUROSCI.3322-08.2008.

6.

Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Gardell LR, Ma JN, Seitzberg JG, Knapp AE, Schiffer HH, Tabatabaei A, Davis CN, Owens M, Clemons B, Wong KK, Lund B, Nash NR, Gao Y, Lameh J, Schmelzer K, Olsson R, Burstein ES.

J Pharmacol Exp Ther. 2008 Dec;327(3):799-808. doi: 10.1124/jpet.108.142570. Epub 2008 Sep 3.

7.

Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.

Gardell LR, Hyldtoft L, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Brann MR, Olsson R, Piu F.

Eur J Pharmacol. 2008 Sep 11;592(1-3):158-9. doi: 10.1016/j.ejphar.2008.06.107. Epub 2008 Jul 4.

PMID:
18644363
8.

Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.

Piu F, Cheevers C, Hyldtoft L, Gardell LR, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Schiffer HH, Donello JE, Olsson R, Gil DW, Brann MR.

Eur J Pharmacol. 2008 Aug 20;590(1-3):423-9. doi: 10.1016/j.ejphar.2008.05.015. Epub 2008 May 23.

PMID:
18559275
9.

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.

Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):129-37. doi: 10.1016/j.jsbmb.2007.11.001. Epub 2007 Nov 22.

PMID:
18164613
10.

Control of chronic pain by the ubiquitin proteasome system in the spinal cord.

Ossipov MH, Bazov I, Gardell LR, Kowal J, Yakovleva T, Usynin I, Ekström TJ, Porreca F, Bakalkin G.

J Neurosci. 2007 Aug 1;27(31):8226-37.

11.

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.

Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW.

J Pharmacol Exp Ther. 2007 Aug;322(2):862-70. Epub 2007 May 22.

12.

Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists.

Ma JN, Schiffer HH, Knapp AE, Wang J, Wong KK, Currier EA, Owens M, Nash NR, Gardell LR, Brann MR, Olsson R, Burstein ES.

Mol Pharmacol. 2007 Aug;72(2):380-6. Epub 2007 May 2.

13.

Dynorphin A activates bradykinin receptors to maintain neuropathic pain.

Lai J, Luo MC, Chen Q, Ma S, Gardell LR, Ossipov MH, Porreca F.

Nat Neurosci. 2006 Dec;9(12):1534-40. Epub 2006 Nov 19.

PMID:
17115041
14.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

15.

Opioid receptor-mediated hyperalgesia and antinociceptive tolerance induced by sustained opiate delivery.

Gardell LR, King T, Ossipov MH, Rice KC, Lai J, Vanderah TW, Porreca F.

Neurosci Lett. 2006 Mar 20;396(1):44-9. Epub 2005 Dec 15.

PMID:
16343768
16.

Role of NK-1 neurotransmission in opioid-induced hyperalgesia.

King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F.

Pain. 2005 Aug;116(3):276-88.

17.

Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.

Xie JY, Herman DS, Stiller CO, Gardell LR, Ossipov MH, Lai J, Porreca F, Vanderah TW.

J Neurosci. 2005 Jan 12;25(2):409-16.

18.

Mouse strains that lack spinal dynorphin upregulation after peripheral nerve injury do not develop neuropathic pain.

Gardell LR, Ibrahim M, Wang R, Wang Z, Ossipov MH, Malan TP Jr, Porreca F, Lai J.

Neuroscience. 2004;123(1):43-52.

PMID:
14667440
19.

Multiple actions of systemic artemin in experimental neuropathy.

Gardell LR, Wang R, Ehrenfels C, Ossipov MH, Rossomando AJ, Miller S, Buckley C, Cai AK, Tse A, Foley SF, Gong B, Walus L, Carmillo P, Worley D, Huang C, Engber T, Pepinsky B, Cate RL, Vanderah TW, Lai J, Sah DW, Porreca F.

Nat Med. 2003 Nov;9(11):1383-9. Epub 2003 Oct 5.

PMID:
14528299
20.

Reversal of experimental neuropathic pain by T-type calcium channel blockers.

Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F.

Pain. 2003 Sep;105(1-2):159-68.

PMID:
14499432
21.

Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation.

Gardell LR, Vanderah TW, Gardell SE, Wang R, Ossipov MH, Lai J, Porreca F.

J Neurosci. 2003 Sep 10;23(23):8370-9.

22.

Dynorphin-independent spinal cannabinoid antinociception.

Gardell LR, Ossipov MH, Vanderah TW, Lai J, Porreca F.

Pain. 2002 Dec;100(3):243-8.

PMID:
12467995
23.

'Knock-down' of spinal CB1 receptors produces abnormal pain and elevates spinal dynorphin content in mice.

Dogrul A, Gardell LR, Ma S, Ossipov MH, Porreca F, Lai J.

Pain. 2002 Nov;100(1-2):203-9.

PMID:
12435473
24.

Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers.

Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP Jr, Lai J, Porreca F.

J Neurosci. 2002 Aug 1;22(15):6747-55.

25.

Pronociceptive effects of spinal dynorphin promote cannabinoid-induced pain and antinociceptive tolerance.

Gardell LR, Burgess SE, Dogrul A, Ossipov MH, Malan TP, Lai J, Porreca F.

Pain. 2002 Jul;98(1-2):79-88.

PMID:
12098619
26.

Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain.

Burgess SE, Gardell LR, Ossipov MH, Malan TP Jr, Vanderah TW, Lai J, Porreca F.

J Neurosci. 2002 Jun 15;22(12):5129-36.

27.

Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor.

Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP Jr, Ossipov MH, Lappi DA, Lai J.

J Neurosci. 2001 Jul 15;21(14):5281-8.

28.

Pronociceptive actions of dynorphin maintain chronic neuropathic pain.

Wang Z, Gardell LR, Ossipov MH, Vanderah TW, Brennan MB, Hochgeschwender U, Hruby VJ, Malan TP Jr, Lai J, Porreca F.

J Neurosci. 2001 Mar 1;21(5):1779-86.

29.

Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, Zhang ET, Malan TP Jr, Ossipov MH, Lai J, Porreca F.

J Neurosci. 2000 Sep 15;20(18):7074-9.

30.

Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats.

Malan TP, Ossipov MH, Gardell LR, Ibrahim M, Bian D, Lai J, Porreca F.

Pain. 2000 May;86(1-2):185-94.

PMID:
10779675
31.

Amlodipine, a calcium channel inhibitor, and cocaine and ethanol's reinforcing effects.

Gardell LR, Reid ML, Cavallero CA, Burgess SE, Wallace RF, Hubbell CL, Reid LD.

Pharmacol Biochem Behav. 1999 Nov;64(3):567-72.

PMID:
10548273
32.

Valproate reduces intake of alcoholic beverage among rats.

Gardell LR, Whalen CA, Chambers MD, Boswell KJ, Hubbell CL, Reid LD.

Behav Pharmacol. 1998 Dec;9(8):683-9.

PMID:
9890258
33.

Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol.

Cramer CM, Gardell LR, Boedeker KL, Harris JR, Hubbell CL, Reid LD.

Pharmacol Biochem Behav. 1998 Jun;60(2):345-56.

PMID:
9632216
34.

Isradipine and naltrexone in combination with isradipine interact with a period of abstinence to reduce rats' intakes of an alcoholic beverage.

Gardell LR, Reid LD, Boedeker KL, Liakos TM, Hubbell CL.

Alcohol Clin Exp Res. 1997 Dec;21(9):1592-8.

PMID:
9438517
35.

Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage.

Gardell LR, Whalen CA, Chattophadyay S, Cavallaro CA, Hubbell CL, Reid LD.

Alcohol Clin Exp Res. 1997 Nov;21(8):1435-9.

PMID:
9394115
36.

Periodic naltrexone and propensity to take alcoholic beverage.

Reid LD, Gardell LR, Chattopadhyay S, Hubbell CL.

Alcohol Clin Exp Res. 1996 Nov;20(8):1329-34.

PMID:
8947306
37.

Naltrexone persistently reduces rats' intake of a palatable alcoholic beverage.

Gardell LR, Hubbell CL, Reid LD.

Alcohol Clin Exp Res. 1996 May;20(3):584-8.

PMID:
8727259

Supplemental Content

Loading ...
Support Center